Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q1 2021 Earnings Presentation
12 slides from Marinomed Biotech's earnings presentation, 2021
Slide 1: Marinomed Biotech AG Update Q1 2021
2021 Marinomed Biotech AG Update Q1
Slide 2: Dear shareholders
2 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Dear shareholders, We all have reason to believe that we are moving Our current priorities are: towards an end of the nearly global lock-down. 1. Focussing on ongoing clinical studies on While advances in COVID vaccination give hope Carragelose efficacy aga
Slide 3: Marinosolv: significant future potential; Substantial growth in Q1/2021
3 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Marinosolv: significant future potential With the ability to provide soluble formulations of even the most hydrophobic substances, the We were also able to achieve important progress Marinosolv technology may increasingly provide a on our Marinosolv project
Slide 4: Outlook for 2021
4 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Outlook for 2021 We confirm our 2021 outlook, the first quarter still Again, we express our thanks to our employees showed pandemic related off-season effects, but for their continued outstanding dedication in these we assume that regular seasonality will r
Slide 5: Statement of profit or loss and other comprehensive income (loss)
5 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Statement of profit or loss and other comprehensive income (loss) all amounts in kEUR 1-3/2021 1-3/2020 Profit or loss Revenues 2,217.2 1,013.9 Other income 467.8 87.3 Other gains (losses), net 11.7 –5.6 Expenses for materials –1,414.5 –673.8 Expenses for s
Slide 6: Statement of financial position
6 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Statement of financial position all amounts in kEUR 31.03.2021 31.12.2020 ASSETS Non-current assets Intangible assets 2,046.1 2,056.8 Property, plant and equipment 6,484.8 6,036.4 Deposits and other non-current receivables 11.8 12.2 8,542.6 8,105.4 Current
Slide 7: Equity and liabilities
7 MAR INOMED BIOTECH AG U P D AT E Q1 2021 all amounts in kEUR 31.03.2021 31.12.2020 Equity and liabilities Capital and reserves Share capital 1,474.7 1,472.7 Capital reserves 41,541.9 41,351.2 Retained losses –39,562.0 –37,466.3 3,454.6 5,357.6 Non-current liabilities Non-current borrowings 12,784.
Slide 8: Statement of cash flows
8 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Statement of cash flows all amounts in kEUR 1-3/2021 1-3/2020 Cash flow utilised by operating activities –3,721.3 –1,588.2 Cash flow utilised by investing activities –404.8 –175.3 Cash flow generated from financing activities 62.2 –26.8 Total change in cash
Slide 9: Statement of changes in equity
9 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Statement of changes in equity all amounts in kEUR Nominal capital/ Capital Retained Total Share capital reserves losses January 1, 2020 1,469.8 40,848.1 –31,451.9 10,866.0 Loss for the period - - –1,574.9 –1,574.9 Total comprehensive income (loss) - - –1,5
Slide 10: Research and development expenses
10 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Research and development expenses Period ended March 31 2021 2020 all amounts in kEUR Personnel expenses –536.0 –422.3 Expenses for services –1,016.2 –165.9 Expenses for materials –105.1 –20.5 Other expenses –91.5 –30.1 Depreciation and amortisation –86.7
Slide 11: Legal notice
11 MAR INOMED BIOTECH AG U P D AT E Q1 2021 Legal notice Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Österreich www.marinomed.com Contact Pascal Schmidt, Chief Financial Officer Tel. +43 2262 90 300-223 ir@marinomed.com Disclaimer Produced in-house in collaboration with ns.publish Due to the
Slide 12: www.marinomed.com
12 MAR INOMED BIOTECH AG U P D AT E Q1 2021 www.marinomed.com